Work with thought leaders and academic experts in drug discovery

Companies can benefit from working with academic researchers in Drug Discovery in several ways. These experts can provide valuable insights and expertise in developing new drugs, conducting preclinical and clinical trials, and optimizing drug discovery processes. They can also offer access to cutting-edge technologies and research facilities, as well as collaborations with other academic institutions and industry partners. Additionally, academic researchers can help companies stay updated with the latest advancements in the field and provide guidance on regulatory requirements and intellectual property issues. By collaborating with academic researchers in Drug Discovery, companies can accelerate their drug development efforts, enhance their scientific credibility, and gain a competitive edge in the market.

Researchers on NotedSource with backgrounds in drug discovery include Aimee Eggler, Regan Hamel, Dr. Everson A Nunes, Ph.D., Claudia Litterst, Brent Banasik, Ph.D., Ajay Badhan, and Ammon Posey.

Aimee Eggler

Villanova, Pennsylvania, United States of America
Professor of Chemistry and Biochemistry at Villanova University
Most Relevant Research Interests
Drug Discovery
Other Research Interests (18)
Biochemistry
Physiology (medical)
Toxicology
Organic Chemistry
Clinical Biochemistry
And 13 more
About
Dr. Eggler has 20 years of experience in the field of redox biology, with a focus on the Nrf2 transcription factor, a master regulator of antioxidant, detoxification and anti-inflammatory genes. She is also an award-winning educator and the recipient of the Villanova University Junior Faculty Excellence in Teaching award. Her interests in education include innovation in teaching metabolism from a logic-based perspective.
Most Relevant Publications (3+)

25 total publications

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

Bioorganic & Medicinal Chemistry Letters / Nov 01, 2013

Turlington, M., Chun, A., Tomar, S., Eggler, A., Grum-Tokars, V., Jacobs, J., Daniels, J. S., Dawson, E., Saldanha, A., Chase, P., Baez-Santos, Y. M., Lindsley, C. W., Hodder, P., Mesecar, A. D., & Stauffer, S. R. (2013). Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorganic & Medicinal Chemistry Letters, 23(22), 6172–6177. https://doi.org/10.1016/j.bmcl.2013.08.112

Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease

Journal of Medicinal Chemistry / Jan 03, 2013

Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., Mielech, A. M., Baker, S. C., Lindsley, C. W., Hodder, P., Mesecar, A., & Stauffer, S. R. (2013). Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. Journal of Medicinal Chemistry, 56(2), 534–546. https://doi.org/10.1021/jm301580n

Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds

Molecules / Apr 03, 2000

Peterson, C., Tsao, R., Eggler, A., & Coats, J. (2000). Insecticidal Activity of Cyanohydrin and Monoterpenoid Compounds. Molecules, 5(12), 648–654. https://doi.org/10.3390/50400648

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Interests
Drug Discovery
Other Research Interests (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (1+)

97 total publications

Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes

Current Drug Targets / Mar 30, 2017

Nunes, E., & Rafacho, A. (2017). Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes. Current Drug Targets, 18(6), 619–628. https://doi.org/10.2174/1389450117666151209120345

See Full Profile

Claudia Litterst

Walnut Creek, California, United States of America
Established PhD research leader with a proven track record of developing innovative assays for the biotech industry
Most Relevant Research Interests
Drug Discovery
Other Research Interests (11)
Cell Biology
Biochemistry
Molecular Biology
Analytical Chemistry
Genetics
And 6 more
About
An established PhD research leader with 15 years of experience in the life sciences and diagnostics industries. Strong expertise in developing innovative PCR assays for oncology and infectious diseases diagnostics. Possessing post-doctoral training in cell-based assay development and high throughput screening for target identification and drug discovery. Academic background in signaling pathways that involve cancer, neurodegenerative and inflammatory diseases. Effective, productive management style to reach shared business goals and objectives. Well versed in the following areas: -Serving as a member of the extended research and development leadership team to support strategic planning initiatives. -Defining and executing experimental plans and protocols. Assuming responsibility for timely completion of activities. -Conducting in-depth analysis and interpretation of experimental data, generating comprehensive summaries, and supporting technical documents, including detailed protocols and reports and communicating progress to stakeholders. -Promoting innovation while adhering to internal and external guidelines and regulatory measures. -Working in a highly cross-functional, fast-paced environment to closely collaborate with business, scientific and medical affairs, legal, engineering, bioinformatics and other R&D teams. -Working with CROs. -Validation testing for hardware instrumentation, reagents and consumables for PCR and transfection. -Serving as subject matter expert for digital PCR.

See Full Profile

Brent Banasik, Ph.D.

Seattle, Washington, United States of America
Unknown affiliation
Most Relevant Research Interests
Drug Discovery
Other Research Interests (12)
synthetic organic chemistry
Cell Biology
Reproductive Medicine
Surgery
Organic Chemistry
And 7 more
About
Enthusiastic synthetic organic chemist with postdoctoral experience and expertise in complex multi-step asymmetric synthesis, medicinal chemistry, discovery, oligonucleotides, DNA sequencing and bioconjugation.
Most Relevant Publications (2+)

11 total publications

Further insight into the asymmetric vinylogous Mukaiyama aldol reaction (VMAR); application to the synthesis of the C27–C45 segment of lagunamide A

Tetrahedron / May 01, 2016

Banasik, B. A., Wang, L., Kanner, A., & Bergdahl, B. M. (2016). Further insight into the asymmetric vinylogous Mukaiyama aldol reaction (VMAR); application to the synthesis of the C27–C45 segment of lagunamide A. Tetrahedron, 72(19), 2481–2490. https://doi.org/10.1016/j.tet.2016.03.079

Lagunamides A and B: Cytotoxic and Antimalarial Cyclodepsipeptides from the Marine Cyanobacterium Lyngbya majuscula

Journal of Natural Products / Oct 11, 2010

Tripathi, A., Puddick, J., Prinsep, M. R., Rottmann, M., & Tan, L. T. (2010). Lagunamides A and B: Cytotoxic and Antimalarial Cyclodepsipeptides from the Marine Cyanobacterium Lyngbya majuscula. Journal of Natural Products, 73(11), 1810–1814. https://doi.org/10.1021/np100442x

See Full Profile

Example drug discovery projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on drug discovery?

Development of Novel Drug Candidates

An academic researcher in Drug Discovery can collaborate with a company to develop novel drug candidates. By leveraging their expertise in molecular biology, pharmacology, and medicinal chemistry, the researcher can identify potential drug targets, design and synthesize new compounds, and evaluate their efficacy and safety. This collaboration can help the company expand its drug pipeline and bring innovative therapies to the market.

Optimization of Drug Discovery Processes

Companies can collaborate with academic researchers to optimize their drug discovery processes. The researcher can provide insights into the latest techniques and technologies for high-throughput screening, virtual screening, and computational modeling. They can also help in streamlining the hit-to-lead and lead optimization stages, improving the efficiency and success rate of drug discovery projects.

Preclinical and Clinical Trials

Academic researchers with expertise in Drug Discovery can assist companies in conducting preclinical and clinical trials. They can design and execute studies to evaluate the safety, efficacy, and pharmacokinetics of potential drug candidates. Their knowledge of regulatory requirements and ethical guidelines ensures that the trials are conducted in compliance with industry standards.

Collaborations with Other Academic Institutions

By collaborating with academic researchers, companies can tap into a network of other experts and institutions in the field of Drug Discovery. These collaborations can lead to joint research projects, knowledge sharing, and access to specialized resources and facilities. Such partnerships can foster innovation and accelerate the development of new drugs.

Intellectual Property and Regulatory Guidance

Academic researchers can provide guidance on intellectual property (IP) and regulatory matters related to drug discovery. They can help companies navigate the complex landscape of patents, copyrights, and licensing agreements. Additionally, they can offer insights into regulatory requirements and assist in preparing documentation for regulatory submissions, ensuring compliance with relevant laws and regulations.